Research programme: STAT3 inhibitors - StemMed

Drug Profile

Research programme: STAT3 inhibitors - StemMed

Alternative Names: C188-9

Latest Information Update: 14 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator StemMed
  • Class Small molecules
  • Mechanism of Action STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Head and neck cancer; Hypersensitivity; Idiopathic pulmonary fibrosis; Inflammatory bowel diseases; Non-small cell lung cancer; Scleroderma

Most Recent Events

  • 19 Jun 2017 StemMed plans a phase I trial for Solid tumours (Late-stage disease) in USA (NCT03195699)
  • 14 Aug 2016 Preclinical trials in Breast cancer in USA (unspecified route)
  • 14 Aug 2016 Preclinical trials in Head and neck cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top